Adagio Medical receives Nasdaq minimum bid price deficiency notice
Adagio Medical Holdings received a notice from Nasdaq on June 12, 2026, that its common stock fell below the minimum bid price requirement of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has until December 9, 2026, to regain compliance; if successful, the stock will continue trading on the Nasdaq Capital Market. A second 180-day cure period may be available if certain conditions are met, but failure to achieve compliance by the end of any cure period will result in a delisting notice.
Key facts
- Minimum bid price below $1.00 per share for 30 consecutive business days
- Compliance deadline: December 9, 2026 (180 calendar days from June 12, 2026)
- Nasdaq Listing Rule 5550(a)(2) violation
- Stock continues trading during cure period
- Potential second 180-day compliance period available if market-cap and other initial listing standards met
- Reverse stock split noted as potential remedy
Why it matters
Adagio Medical has six months to restore its stock price above $1.00 per share or pursue a reverse split to avoid delisting from Nasdaq Capital Market; failure to act risks losing its exchange listing.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-12. Not investment advice. View the source filing on SEC.gov →